Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Topas Therapeutics

Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego
From Topas Therapeutics
Via Business Wire
Topas Therapeutics Publishes Foundational Data Demonstrating Tolerance Induction by its Proprietary Nanoparticle Platform in Frontiers in Immunology
From Topas Therapeutics
Via Business Wire
Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease
From Topas Therapeutics
Via Business Wire
Topas Therapeutics Appoints Hugo Fry as CEO
From Topas Therapeutics
Via Business Wire
Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer
From Topas Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.